DC Vaccine + Cyclophosphamide

The combination of dendritic cell (DC) vaccines with cyclophosphamide represents an innovative immunotherapeutic approach that has been studied in various cancer types. This combination therapy aims to enhance anti-tumor immune responses by leveraging the immunomodulatory effects of low-dose cyclophosphamide alongside the immune-stimulating properties of dendritic cell vaccines. ## Mechanism of Action Dendritic cell vaccines work by presenting tumor antigens to the immune system, particularly T cells, to stimulate an anti-tumor immune response. Cyclophosphamide, when administered at low doses, has been found to selectively deplete regulatory T cells (Tregs), which normally suppress immune responses. By reducing Treg activity, cyclophosphamide creates a more favorable environment for the DC vaccine to generate effective anti-tumor immunity. The synergistic effect occurs because: 1. Low-dose cyclophosphamide prevents the induction of regulatory T cells (Tregs) that would otherwise suppress cytotoxic T cell function[1]. 2. This immunomodulatory effect enhances the ability of DC vaccines to stimulate tumor-specific immune responses[1][4]. 3. The combination promotes differentiation of effector CD4+ T cells, particularly T helper 1 (Th1) cells that produce IFN-γ and IL-2[4]. ## Clinical Applications This combination therapy has been studied in several cancer types: - **Malignant Melanoma**: Clinical trials have shown that combining DC vaccines with low-dose cyclophosphamide can increase the proportion of patients achieving stable disease compared to DC vaccination alone[2]. - **Mesothelioma**: Studies in tumor-bearing mice demonstrated that adding cyclophosphamide to DC-based immunotherapy improved median and overall survival[1]. - **Ovarian Cancer**: Research has shown varying results, with one study reporting that 2-year overall survival rates were 80% for patients receiving cyclophosphamide prior to DC vaccines compared to 30% for those receiving DC vaccines alone[5]. - **Pediatric Cancers**: The combination has been investigated as part of multimodal individualized therapy for high-risk pediatric cancer patients[7]. ## Dosing Regimen The typical cyclophosphamide regimen used in these studies is metronomic (low-dose), often administered as: - 50 mg twice daily for one week every two weeks[2][3] - This low-dose approach is specifically designed to achieve immunomodulatory effects rather than cytotoxic effects[4]. ## Safety Profile The combination of DC vaccination and cyclophosphamide has generally been reported as well-tolerated in clinical trials[2]. However, the specific effect on Treg levels has shown some variability across studies, with some reporting increased rather than decreased Treg levels during treatment[2][3]. ## Development Status This combination therapy remains primarily investigational, with numerous clinical trials evaluating its efficacy in various cancer types. While showing promise in extending survival and disease stabilization in some studies, it has not yet received regulatory approval as a standard treatment approach. The research suggests that this combination therapy represents a promising strategy for enhancing cancer immunotherapy, though further optimization and larger clinical trials are needed to establish its place in standard treatment protocols.

Brand names

MesoCancerVacEndoxan

Other names

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamideautologous tumor lysate-pulsed dendritic cells + cyclophosphamideDC + CTX-Erasmus Medical Center